Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2022 Earnings Call Transcript

Rick Winningham: Yes, sure. We would expect composition of matter with patent term extension to be out to 2035. And then beyond that, for ampreloxetine in the use of nOH. have added a new slide to the deck Slide 26, which outlines the patent protection for both YUPELRI and ampreloxetine.

Liisa Bayko: Okay, great. Thank you very much.

Operator: This does conclude the question-and-answer session of today’s program. I’d like to hand the program back to Mr. Winningham for any further remarks.

Rick Winningham: Yes, I’d just like to thank everyone for joining us today on this important call outlining both the strategic actions that we’ve taken and the review of 2022 performance and the outlook of — for 2023. We’re excited about what we can accomplish in the business in 2023 with the focus on YUPELRI and ampreloxetine, and we look forward to bringing you updates as we work through the year and work through the important capital return program and increase of which we highlighted today. So please have a good day, and thank you for joining us.

Operator: Thank you, ladies and gentlemen, for your participation in today’s conference. This does conclude the program. You may now disconnect. Good day.